Kacew Alec J, Hanna Glenn J
Biological Sciences Division, Pritzker School of Medicine, The University of Chicago, 924 E 57th St, Chicago, IL 60637, USA.
Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.
Cancers (Basel). 2021 Feb 2;13(3):562. doi: 10.3390/cancers13030562.
The burden of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has risen, now representing the most common HPV-related malignancy. For years, researchers have explored the utility of measuring HPV-related markers from mouth, throat, and blood samples, often with the aim of gathering more information about an existing HPV-related tumor in a given patient. We review the widely varying methods for collecting and testing saliva and blood samples and offer guidance for standardizing these practices. We then review an array of clinical contexts in which non-invasive testing holds the most promise for potentially addressing unmet needs. In particular, such testing could help clinicians and researchers monitor the effects of vaccination and treatment. Meanwhile, due to the currently incomplete understanding of how carrying HPV relates to infection and subsequent oncogenesis, non-invasive testing methods may not be suitable for the screening setting at this time.
人乳头瘤病毒(HPV)相关口咽癌(OPC)的负担有所上升,现已成为最常见的HPV相关恶性肿瘤。多年来,研究人员一直在探索从口腔、咽喉和血液样本中检测HPV相关标志物的效用,目的通常是收集更多关于特定患者现有HPV相关肿瘤的信息。我们回顾了收集和检测唾液及血液样本的广泛不同方法,并为规范这些操作提供指导。然后,我们回顾了一系列临床情况,在这些情况下,非侵入性检测最有希望满足未满足的需求。特别是,这种检测可以帮助临床医生和研究人员监测疫苗接种和治疗的效果。同时,由于目前对携带HPV与感染及随后的肿瘤发生之间的关系了解不完整,非侵入性检测方法目前可能不适用于筛查。